In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma .
http://www.biosciencetechnology.com/news/2013/06/ibrutinib-continues-strong-showing-against-mantle-cell-lymphoma
http://www.biosciencetechnology.com/news/2013/06/ibrutinib-continues-strong-showing-against-mantle-cell-lymphoma
No comments:
Post a Comment